AbCellera to report Phase 2 top-line data for menopause hot flash drug ABCL635 on Aug. 10

AbCellera scheduled top-line Phase 2 results for ABCL635 in moderate-to-severe menopausal vasomotor symptoms for Aug. 10, 2026, before market open.

Data release will clarify whether the candidate showed a meaningful clinical benefit in easing symptoms, shaping next-step development and funding priorities.

An investor conference call is set for 4:30 a.m. PT to discuss the readout.